Vetr Crowd Bearish On GW Pharma, But Upgrades To 3-Star Rating
GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) has risen to $91.57 since its previous Vetr rating of 2.5 stars was issued two days ago. On Friday, the Vetr community upgraded their rating to three stars.
The British pharmaceutical company rallied on Tuesday on the release of positive data from their drug Epidiolex.
Overall though, sentiment on Vetr is bearish. Less than 2 percent of Vetr users are holding it in their watch-lists, and 57 percent of the crowd's ratings are bearish. The Vetr crowd sees a price target of $89.66, compared to analyst projections $131.25.
See how Vetr's crowdsourced ratings can help you beat the market.
At time of writing, GW Pharma was up 1.64 percent at $93.07.
Latest Ratings for GWPH
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2021 | Morgan Stanley | Downgrades | Overweight | Equal-Weight |
| Feb 2021 | HC Wainwright & Co. | Downgrades | Buy | Neutral |
| Feb 2021 | SVB Leerink | Downgrades | Outperform | Market Perform |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Analyst Color Biotech Downgrades Health Care Crowdsourcing Analyst Ratings Trading Ideas General
